ARCHIVEHow Bodyform's #Periodsomnia Campaign Broke the Period Sleep Taboo
How Bodyform's #Periodsomnia Confronts Period Sleep Loss in the United Kingdom and United States...
VABYSMO Reframes Pharma Storytelling With A Beautiful Sight
VABYSMO's A Beautiful Sight is a short animated film created by Grey Health for Genentech, released in the United States on May 7, 2024, to coincide with Mother's Day, addressing wet age-related macular degeneration — the leading cause of vision loss among older adults in the US — through emotionally driven narrative rather than clinical messaging.
Genentech positioned A Beautiful Sight as a deliberate departure from conventional pharmaceutical advertising. Rather than leading with treatment efficacy data or symptom catalogues, the campaign constructs a dual narrative: a mother's progressive vision loss runs parallel to her son's journey to become a retina specialist, told through a first-person point-of-view framework that makes vision itself the emotional and literal subject of the film. The approach is designed to move three distinct audiences simultaneously — patients living with wet AMD, family caregivers, and the retinal specialists who prescribe VABYSMO — a strategic scope rarely attempted within a single branded pharmaceutical asset.
Genentech Patient Marketing Director for Ophthalmology Erin Echter described the campaign's ambition in coverage published by the 4A's: the team sought to flip the script on traditional pharma ads by centering human experience over clinical function, demonstrating that VABYSMO is not merely a treatment but one a retina specialist would trust for their own parents. That framing — physician-as-son, patient-as-mother — gives the film a credibility architecture that clinical claims alone cannot provide. In the United States, where direct-to-consumer pharmaceutical advertising operates under strict regulatory constraint, emotional resonance of this kind represents a significant creative risk and, when executed with craft, a significant competitive differentiator. The Clapboard Score for A Beautiful Sight is 69 out of 100, reflecting strong creative ambition measured against the structural challenges of regulated healthcare communications.
VABYSMO entered its second year of direct-to-consumer activity in the United States facing an entrenched competitive landscape. Eylea, marketed by Regeneron and Bayer, held an estimated 51.8% share of the anti-VEGF market in 2024 under one market definition, according to hdinresearch.com, making it the dominant incumbent against which VABYSMO measured every brand-building move. Legacy Eylea sales reached approximately $3.76 billion and Eylea HD approximately $0.71 billion in the same period, per hdinresearch.com, underscoring the scale of the opposition. North America held more than 45% of the broader anti-VEGF market in 2024, according to sphericalinsights.com, anchoring the strategic importance of the US market to Genentech's global ambitions for the brand.
Genentech had already established VABYSMO's consumer presence through its 2023 campaign, Open Up Your World with Vabysmo, which launched approximately one year before A Beautiful Sight, as reported by fiercepharma.com. That earlier effort deployed live-action imagery across national television, online video, audio, digital channels, print, and physician-office materials, per fiercepharma.com, building foundational brand recognition. A Beautiful Sight did not replicate that broad-channel approach. Instead, Grey Health identified a more concentrated strategic insight: that the emotional stakes of vision loss are most powerfully communicated through the people who experience them together — patients and the family members who become their caregivers, including, in real documented cases, the retinal specialists whose professional calling began at home. This insight, grounded in real-life stories of retinal specialists caring for their own parents, gave the campaign an authenticity that distinguishes it from category convention. Lucentis, another anti-VEGF treatment in the US market, represents a further competitive pressure point, reinforcing the need for VABYSMO to build emotional differentiation beyond shared clinical mechanisms.
A Beautiful Sight was produced by Roof Studio, the New York-based animation production company, under the creative direction of Grey Health New York. The film's animated format is itself a strategic creative decision: animation allows the first-person point-of-view construct to render vision loss and restored clarity in ways live-action cinematography cannot replicate without resorting to clinical literalism. The result is a visual language that is simultaneously metaphorical and medically grounded, a balance that regulated pharmaceutical advertising rarely achieves.
Bruno Rebelo served as Executive Creative Director on the campaign, as documented by adforum.com and reel360.com, with creative direction shared by Doug Flynn and Luis Bacellar. Associate creative directors Casey Espinoza and Sahar Sehgaal contributed to the work, alongside producer Vivi Torre, per adforum.com. Direction of the animated film is credited to Guto Terni and Vinicius Costa, with Lucas Camargo also listed as director, according to reel360.com. The score was composed by Joel P. West — a collaborator associated with major film productions including Marvel's Shang-Chi — whose involvement signals the production's aspiration to feature-film-grade sonic craft within a pharmaceutical brand context. As reported by Ads of Brands on June 14, 2024, West's musical contribution was specifically noted as central to the campaign's emotional architecture, reinforcing how sound design and narrative pacing were treated as inseparable from the visual storytelling rather than supplementary to it. AdForum included A Beautiful Sight in its Top 5 Ads beauty-and-health selection on May 22, 2024, describing the film as heartwarming, according to adforum.com. The production represents one of the more ambitious applications of animation craft within US branded pharmaceutical advertising in 2024.
VABYSMO recorded a market share increase from 24% to 27% within one quarter following the campaign, a 3-percentage-point gain documented by oneclub.org. That figure carries material significance in the US anti-VEGF category, where Eylea's entrenched position — at an estimated 51.8% share per hdinresearch.com — makes every incremental point of share gain a consequential commercial outcome. The campaign also generated a 6-times lift in Estimated Ad Recall Lift among healthcare professionals, as reported by oneclub.org, a metric that speaks directly to the physician-audience targeting that Grey Health built into the film's structural strategy.
A Beautiful Sight received a Bronze award in the Branded Entertainment and Content Campaign of the Year category at the Healthcare Marketing Impact Awards in 2024, as reported by Grey Health's Liz Shaw via linkedin.com. The One Club documented the campaign and its results, though available records do not establish a verified award win from that organisation, per oneclub.org. Taken together, the performance data — share growth, ad recall lift, and industry recognition — substantiates the campaign's core strategic premise: that emotional storytelling directed at patients, caregivers, and prescribers simultaneously can move commercial metrics in a heavily regulated category. The 4A's published coverage on June 24, 2024, quoting both Erin Echter and Bruno Rebelo on the campaign's intentional departure from clinical-functional pharmaceutical advertising norms, per aaaa.org, providing further third-party validation of the approach. A Clapboard Score of 69 out of 100 positions A Beautiful Sight as a craft-forward effort that achieves meaningful results within the structural constraints of US pharmaceutical marketing regulation.
A Beautiful Sight is a short animated film created by Grey Health for Genentech's VABYSMO, released in the United States on May 7, 2024, for Mother's Day. It addresses wet age-related macular degeneration through a first-person narrative pairing a mother's vision loss with her son's path to becoming a retina specialist, targeting patients, caregivers, and physicians simultaneously.
Grey Health New York created A Beautiful Sight for Genentech's VABYSMO in 2024. Executive Creative Director Bruno Rebelo led the team, with Roof Studio handling animation production, directors Guto Terni and Vinicius Costa at the helm, and composer Joel P. West — known for his work on Marvel's Shang-Chi — providing the film's score, as documented by adforum.com and reel360.com.
A Beautiful Sight won a Bronze award in the Branded Entertainment and Content Campaign of the Year category at the 2024 Healthcare Marketing Impact Awards, as reported by Grey Health's Liz Shaw via linkedin.com. AdForum also selected the campaign for its Top 5 Ads health-and-beauty list in May 2024, according to adforum.com, recognising its storytelling craft within pharmaceutical advertising.
VABYSMO's US market share increased from 24% to 27% within one quarter following the campaign's launch, according to oneclub.org. The campaign also delivered a 6-times lift in Estimated Ad Recall Lift among healthcare professionals, per oneclub.org, demonstrating measurable impact across both the physician prescriber audience and broader brand awareness objectives in the United States.
Grey Health and Roof Studio chose animation to render a first-person experience of vision loss and restored sight in ways live-action production cannot achieve without clinical literalism. The format, combined with composer Joel P. West's score, allowed the team to communicate the emotional stakes of wet age-related macular degeneration for patients, caregivers, and retina specialists simultaneously, as noted by Ads of Brands in June 2024.
VABYSMO's prior US campaign, Open Up Your World with Vabysmo, launched in 2023 using live-action formats across television, digital, and print channels, as reported by fiercepharma.com. A Beautiful Sight shifted to animated storytelling and concentrated on emotional human experience over clinical messaging, targeting patients, caregivers, and retina specialists through a single narrative rather than broad-channel product communication.
.webp)
Creative Collaboration Platform: The Backbone of Modern Creative WorkWhat is a creative collaboration platform?Clapboard defines a creative collaboration platform as the operational core for today’s distributed creative teams. This is not a collection of digital collaboration tools stitched together; Clapboard’s system
Understanding the Creative Production MarketplaceWhat is a Creative Production Marketplace?Clapboard defines a creative production marketplace as a structured ecosystem where brands, agencies, and production talent converge to execute video, advertising, and branded content at scale. Unlike the legacy agency or freelanREAD FULL ARTICLE
The Urgent Need for a Creative Production Operating SystemWhy Traditional Creative Production Models Break DownClapboard sees the creative production landscape shifting under pressure. Content velocity is no longer a buzzword—it’s a mandate. Modern advertising demands relentless output across dozens of channels, each wREAD FULL ARTICLE
.jpg&w=256&q=75)
